• Home
  • Search Results

Search Results

Young Adult (18-34)
Transplant
18 studies match your search
Open

A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

Are you diagnosed with chronic graft versus host disease (cGVHD)? If so, you might be able to take part in a study to evaluate the safety and efficacy of belumosudil in combination with corticosteroids.

Age & Gender
  • 12 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Not currently enrolling

Financial Assistance Research

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Aging
  • Behavior
  • Blood Pressure
  • and 44 more
Visit Location
100% Remote (online, phone, text)
Open

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
  • Transplant
Open

Tracking the Impact of Kidney Transplant

Have you been listed for kidney transplant at UNC? If so, you may be able to take part in a research study to help us learn how the process of waiting for a kidney transplant impacts you.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Genetics and Genetic Disorders
  • Mental and Emotional Health
  • Transplant
  • and 3 more
Visit Location
100% Remote (online, phone, text)
Open

Study to evaluate the safety and effectiveness of a single dose of EDIT-301 in individuals with severe Sickle Cell Disease (SCD)

Do you have severe sickle cell disease? If so, you may be eligible to participate in a research study that is looking at the safety and effectiveness of using your own modified stem cells as possible treatment.

Age & Gender
  • 12 years ~ 50 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Chronic Conditions
  • Genetics and Genetic Disorders
  • Transplant
Open

Long-term immunologic responses to COVID-19 infection and vaccination

Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).

Age & Gender
  • 7 years ~ 95 years
  • Male, Female, Gender Inclusive
Study Interest
  • Child and Teen Health
  • Immune System/Infections
  • COVID-19
  • and 2 more
By physician referral or invitation only

Assessing treatment preferences and quality of life of high-risk skin lesions in solid organ transplant recipients: a cross-sectional study

To collect quantitative data to: -Primarily gain a better understanding of patients' attitudes and preferences regarding end-of-life care management if they were to develop a high-risk skin cancer. To be more specific, we hope to gain a better understanding of how patients weigh their risk of developing skin cancer while taking immunosuppressants versus the risk of transplant rejection should they choose to stop or lower their immunosuppressants. -Determine how far these kidney transplant recipients travel to obtain skin-related care -Determine how frequently kidney transplant recipients obtain skin exams -Determine patients' baseline knowledge regarding risk of skin cancer while taking immunosuppressants, which are medicines that lowers immune systems -Determine the quality of life of individuals with skin cancer who are kidney transplant recipients

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Other Cancers)
  • Kidneys and Liver
  • Skin, Hair, and Nails
  • Transplant
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Comparative effectiveness and safety of belatacept among kidney transplant recipients

Belatacept is a drug that helps kidney transplant recipients by preventing the body from rejecting the new organ. We want to compare how well belatacept works compared to the commonly used drug tacrolimus. To do this, we plan to study people who got kidney transplants in the United States from 2011 to 2020. By using two large databases, the United States Renal Data System, and the Scientific Registry of Transplant Recipients, we aim to understand how belatacept is used in real life. We are also interested in comparing how effective and safe is belatacept compared with tacrolimus after one year of administration. We will look at outcomes like how long the transplanted kidney will work, how long will the kidney transplant recipients live, how well your kidneys will work, the risk of organ rejection, and certain side effects to happen after transplant like blood cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Immune System/Infections
  • Kidneys and Liver
  • Transplant
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Pediatric Chronic Kidney Disease Research Registry

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.

Age & Gender
  • 0 years ~ 25 years
  • Male, Female, Gender Inclusive
Study Interest
  • Child and Teen Health
  • Developmental
  • Transplant
  • and 2 more
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research